| Absorption | Azacitidine is rapidly absorbed after subcutaneous administration. The bioavailability of subcutaneous azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve. |
| Volume of distribution |
|
| Protein binding | Not Available |
| Metabolism | An in vitro study of azacitidine incubation in human liver fractions indicated that azacitidine may be metabolized by the liver. The potential of azacitidine to inhibit cytochrome P450 (CYP) enzymes is not known. |
| Route of elimination | Following IV administration of radioactive azacitidine to 5 cancer patients, the cumulative urinary excretion was 85% of the radioactive dose. Fecal excretion accounted for <1% of administered radioactivity over three days. Mean excretion of radioactivity in urine following SC administration of 14C-azacitidine was 50%. |
| Half life | Mean elimination half-life is approximately 4 hours. |
| Clearance |
|
| Toxicity | One case of overdose with azacitidine was reported during clinical trials. A patient experienced diarrhea, nausea, and vomiting after receiving a single IV dose of approximately 290 mg/m2, almost 4 times the recommended starting dose. |
| Affected organisms |
|
Azacitidine
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment